Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ Aegera Therapeutics
Aegera Therapeutics
Industry · 9 registered clinical trials.
Status
Trial
Phase
Started
Terminated
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard
Leukemia
Phase 2
2009-11-01
Completed
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Advanced Hepatocellular Carcinoma
Phase 1 / Phase 2
2009-03-01
Completed
Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy, Chronic Pain
Phase 2
2009-03-01
Terminated
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphoc
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
Phase 1 / Phase 2
2008-09-01
Terminated
A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer
Human Mammary Carcinoma
Phase 1 / Phase 2
2007-11-01
Terminated
A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell L
Carcinoma, Non-Small-Cell Lung
Phase 1 / Phase 2
2007-09-01
Terminated
A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
Carcinoma, Pancreas
Phase 1 / Phase 2
2007-09-01
Terminated
Study of XIAP Antisense for Advanced Cancers
Advanced Cancer
Phase 1
2006-06-01
Completed
Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
Leukemia, Myelomonocytic, Acute
Phase 1 / Phase 2
2005-10-01